Table 4.

Changes in symptoms and signs in the subgroups with low or near-normal baseline subbasal nerve fiber length (SNFL) after 4 weeks of treatment with loteprednol etabonate/tobramycin.

	Low SNFL (<16.84 mm/mm2) n=8			Near-normal SNFL (≥16.84 mm/mm2) n=9
	Baseline	4 Weeks	P value	Baseline	4 Weeks	P value
OSDI	58.8 ± 21.3	62.9 ± 24.1	0.56	60.5 ± 15.7	51.0 ± 20.5	0.09
SANDE Frequency	78.3 ± 17.2	64.0 ± 28.6	0.28	77.5 ± 11.9	67.5 ± 30.8	0.35
SANDE Severity	65.1 ± 20.8	65.8 ± 28.2	0.96	68.7 ± 20.1	63.4 ± 25.1	0.63
Corneal Fluorescein Staining (NEI scale)	6.5 ± 3.0	6.9 ± 4.5	0.72	7.0 ± 2.3	5.7 ± 4.0	0.39
Tear Break-up Time (seconds)	2.6 ± 2.4	2.9 ± 3.2	0.73	3.0 ± 2.2	2.7 ± 2.3	0.72
Conjunctival Lissamine Green Staining (NEI scale)	1.3 ± 1.7	1.9 ± 1.6	0.46	3.4 ± 2.3	2.8 ± 2.6	0.43
Schirmer’s Test (mm)	7.3 ± 10.1	3.8 ± 5.0	0.14	4.3 ± 3.4	3.8 ± 6.0	0.76